By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

bioTheranostics 

9640 Towne Centre Drive
Suite 200
San Diego  California  92121  U.S.A.
Phone: 858-587-5870 Fax: 858-587-5871


SEARCH JOBS



Key Statistics


Email: molecular@biotheranostics.com
Ownership: Private

Web Site: bioTheranostics
Employees:
Symbol: 
 



Industry
Diagnostics






Company News
New Data From bioTheranostics Further Demonstrate The Value Of CancerTYPE ID To Help Identify Metastatic Cancers With An Unknown Or Unclear Tumor Type Diagnosis 6/9/2017 7:28:13 AM
bioTheranostics Release: New Data Affirms Value Of Breast Cancer Index (BCI) In Identification Of Early Stage ER+ Breast Cancer Patients Appropriate For Extended Endocrine Therapy (EET) 6/5/2017 11:09:09 AM
bioTheranostics Names Don Hardison as New CEO 5/18/2017 7:40:15 AM
bioTheranostics Presents First Data From The BCI Clinical Database For Correlative Studies 5/2/2017 7:25:32 AM
bioTheranostics Release: Study Demonstrates Use Of Breast Cancer Index(SM) (BCI) Leads To Significant Changes In Physician Recommendations For Extended Endocrine Therapy In ER+ Breast Cancer Patients 3/13/2017 8:54:23 AM
bioTheranostics Release: Study Presented At San Antonio Breast Cancer Symposium Demonstrates Strong Performance Of Biotheranostics’ 92-Gene Assay In The Diagnosis Of Triple Negative Breast Cancer 12/12/2016 8:36:04 AM
bioTheranostics Release: New Data Substantiate The Ability Of Breast Cancer Index(SM) To Help Physicians Identify Early Stage ER+ Breast Cancer Patients For Extended Anti-Estrogen Therapy 12/8/2016 9:19:56 AM
bioTheranostics & Syapse Collaborate To Integrate Genomics-Based Molecular Diagnostics For Cancer Into The Syapse Precision Medicine Platform 9/22/2016 12:56:46 PM
bioTheranostics Appoints Industry Veteran Don Hardison To Board Of Directors 7/20/2016 8:52:36 AM
ASCO2016: bioTheranostics Release: New Data Presented At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting Expand Clinical Utility Of Breast Cancer Index(SM) In The Extended Adjuvant Setting To Include Early-Stage, ER+ Patients With Up To Three Positive Nodes 6/6/2016 12:30:57 PM
123456
//-->